Executive Briefing Series (formerly The Food & Drug Letter)
Oct. 5, 2012
FDA Studying Inclusion of Risk/Benefit Information in DTC Advertising
The FDA needs more time to make a decision about whether risk/benefit information should be added to prescription drug promotional labeling or advertising, the agency said in a recent report to Congress.
This article is viewable by subscribers only. To view this article, please select an option below.